<DOC>
	<DOC>NCT02905331</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy, safety, pharmacokinetics, immunogenicity, usability, and acceptability of guselkumab delivered using SelfDose device in participants with moderate to severe plaque-type psoriasis.</brief_summary>
	<brief_title>Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>A woman of childbearing potential must have a negative urine pregnancy test (betahuman chorionic gonadotropin) at screening and at Week 0 Before randomization, a woman must be either: a) Not of childbearing potential: premenarchal; postmenopausal (greater than [&gt;] 45 years of age with amenorrhea for at least 12 months or any age with amenorrhea for at least 6 months and a serum folliclestimulating hormone level (FSH) &gt;40 International Units Per Liter [IU/L]); permanently sterile (example, tubal occlusion, hysterectomy, bilateral salpingectomy); or otherwise be incapable of pregnancy, b) Of childbearing potential and practicing a highly effective method of birth control, consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies: example, established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device (IUD) or intrauterine system (IUS); barrier methods: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal foam/gel/ film/cream/suppository (if available in their locale); male partner sterilization (the vasectomized partner should be the sole partner for that participant); true abstinence (when this is in line with the preferred and usual lifestyle of the participant) Agree not to receive a Bacillus Calmette Guerin (BCG) vaccination during the study, or within 12 months after the last administration of study drug Have a Psoriasis Area and Severity Index (PASI) greater than or equal to [&gt;=] 12 at screening and at baseline Have an involved body surface area (BSA) &gt;= 10 percent (%) at screening and at baseline Has unstable cardiovascular disease, defined as a recent clinical deterioration (eg, unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months Has a history of lymphoproliferative disease, including lymphoma; a history of monoclonal gammopathy of undetermined significance (MGUS); or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy or splenomegaly Has a transplanted organ (with exception of a corneal transplant &gt;3 months before the first administration of study drug) Has a nonplaque form of psoriasis (example, erythrodermic, guttate, or pustular) Has received any antitumor necrosis factor alpha (TNFalpha) biologic therapy within 3 months before the first administration of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>